Nektar Therapeutics Inc. Insider Trading

NKTR

Last 12 months

Insiders sold $2.43M and bought nothing on the open market.

86% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Sep 2019.

Net open-market

−$2.43M

0 buys · 13 sales

Under a 10b5-1 plan

86%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Sep 2019

Sep 5, 2019

Get an email when NKTR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 18	Jonathan Zalevsky Chief R&D Officer	SoldNo plan	186	$71.98	13K	1.9%	Form 4
Aug 18	Howard W Robin President & CEO	SoldNo plan	418	$71.98	30K	0.8%	Form 4
Jun 30	Jonathan Zalevsky Chief R&D Officer	Sold10b5-1 plan	5,681	$70.00	398K	37%	Form 4
Jun 16 – 17	Howard W Robin President & CEO	Sold10b5-1 plan 4 parts	20,000	$60.75 average	$1.22M	27%	Form 4
Jun 15	Jonathan Zalevsky Chief R&D Officer	Sold10b5-1 plan	5,538	$60.71	336K	26%	Form 4
May 19	Jonathan Zalevsky Chief R&D Officer	SoldNo plan	199	$65.51	13K	0.9%	Form 4
May 19	Howard W Robin President & CEO	SoldNo plan	444	$65.51	29K	0.6%	Form 4
Feb 18	Jonathan Zalevsky Chief R&D Officer	SoldNo plan	180	$73.00	13K	0.8%	Form 4
Feb 18	Howard W Robin President & CEO	SoldNo plan	423	$73.00	31K	0.6%	Form 4
Jan 20	Jonathan Zalevsky Chief R&D Officer	Sold10b5-1 plan	3,867	$35.67	138K	15%	Form 4
Nov 25, 2025	Jonathan Zalevsky Chief R&D Officer	SoldNo plan	1,157	$54.28	63K	5.7%	Form 4
Nov 25, 2025	Mark Andrew Wilson Chief Legal Officer	SoldNo plan	630	$54.28	34K	2.8%	Form 4
Nov 25, 2025	Howard W Robin President & CEO	SoldNo plan	2,207	$54.28	120K	3.9%	Form 4
Sep 9, 2025	Howard W Robin President & CEO	Sold10b5-1 plan 4 parts	6,666	$46.69 average	311K	12%	Form 4
Sep 4, 2025 – Sep 5, 2025	Howard W Robin President & CEO	Sold10b5-1 plan 7 parts	11,832	$36.42 average	431K	17%	Form 4
Sep 4, 2025	Jonathan Zalevsky Chief R&D Officer	Sold10b5-1 plan 4 parts	1,721	$33.52 average	58K	9.0%	Form 4
Sep 2, 2025	Jonathan Zalevsky Chief R&D Officer	Sold10b5-1 plan	485	$30.10	15K	2.5%	Form 4
Sep 2, 2025	Howard W Robin President & CEO	Sold10b5-1 plan	1,500	$30.16	45K	2.2%	Form 4
Aug 19, 2025	Jonathan Zalevsky Chief R&D Officer	SoldNo plan	725	$26.59	19K	3.6%	Form 4
Aug 19, 2025	Mark Andrew Wilson Chief Legal Officer	SoldNo plan	676	$26.59	18K	3.2%	Form 4
Aug 19, 2025	Howard W Robin President & CEO	SoldNo plan	1,573	$26.59	42K	2.2%	Form 4
May 19, 2025	Jonathan Zalevsky Chief R&D Officer	SoldNo plan	10,712	$0.67	7K	3.4%	Form 4
May 19, 2025	Mark Andrew Wilson Chief Legal Officer	SoldNo plan	9,996	$0.67	7K	3.1%	Form 4
May 19, 2025	Howard W Robin President & CEO	SoldNo plan	23,208	$0.67	16K	2.1%	Form 4
Feb 19, 2025	Jonathan Zalevsky Chief R&D Officer	SoldNo plan	10,300	$1.01	10K	3.2%	Form 4
Feb 19, 2025	Mark Andrew Wilson Chief Legal Officer	SoldNo plan	11,040	$1.01	11K	3.3%	Form 4
Feb 19, 2025	Howard W Robin President & CEO	SoldNo plan	23,774	$1.01	24K	2.1%	Form 4
Dec 23, 2024 – Dec 24, 2024	Mark Andrew Wilson Chief Legal Officer	SoldNo plan 2 parts	49,962	$0.90 average	45K	13%	Form 4
Dec 19, 2024	Jonathan Zalevsky Chief R&D Officer	SoldNo plan	51,115	$0.94	48K	14%	Form 4
Dec 17, 2024 – Dec 18, 2024	Howard W Robin President & CEO	SoldNo plan 2 parts	132,030	$1.00 average	132K	11%	Form 4
Nov 19, 2024	Jonathan Zalevsky Chief R&D Officer	SoldNo plan	7,785	$1.01	8K	3.1%	Form 4
Nov 19, 2024	Mark Andrew Wilson Chief Legal Officer	SoldNo plan	6,407	$1.01	6K	2.8%	Form 4
Nov 19, 2024	Howard W Robin President & CEO	SoldNo plan	16,278	$1.01	16K	1.9%	Form 4

Aug 18No plan
Jonathan Zalevsky
Chief R&D Officer · sold 186 at $71.98
13K
1.9% of stake
Aug 18No plan
Howard W Robin
President & CEO · sold 418 at $71.98
30K
0.8% of stake
Jun 3010b5-1 plan
Jonathan Zalevsky
Chief R&D Officer · sold 5,681 at $70.00
398K
37% of stake
Jun 16 – 1710b5-1 plan
Howard W Robin
President & CEO · sold 20,000 at avg $60.75
$1.22M
27% of stake
Jun 1510b5-1 plan
Jonathan Zalevsky
Chief R&D Officer · sold 5,538 at $60.71
336K
26% of stake
May 19No plan
Jonathan Zalevsky
Chief R&D Officer · sold 199 at $65.51
13K
0.9% of stake
May 19No plan
Howard W Robin
President & CEO · sold 444 at $65.51
29K
0.6% of stake
Feb 18No plan
Jonathan Zalevsky
Chief R&D Officer · sold 180 at $73.00
13K
0.8% of stake
Feb 18No plan
Howard W Robin
President & CEO · sold 423 at $73.00
31K
0.6% of stake
Jan 2010b5-1 plan
Jonathan Zalevsky
Chief R&D Officer · sold 3,867 at $35.67
138K
15% of stake
Nov 25, 2025No plan
Jonathan Zalevsky
Chief R&D Officer · sold 1,157 at $54.28
63K
5.7% of stake
Nov 25, 2025No plan
Mark Andrew Wilson
Chief Legal Officer · sold 630 at $54.28
34K
2.8% of stake
Nov 25, 2025No plan
Howard W Robin
President & CEO · sold 2,207 at $54.28
120K
3.9% of stake
Sep 9, 202510b5-1 plan
Howard W Robin
President & CEO · sold 6,666 at avg $46.69
311K
12% of stake
Sep 4, 2025 – Sep 5, 202510b5-1 plan
Howard W Robin
President & CEO · sold 11,832 at avg $36.42
431K
17% of stake
Sep 4, 202510b5-1 plan
Jonathan Zalevsky
Chief R&D Officer · sold 1,721 at avg $33.52
58K
9.0% of stake
Sep 2, 202510b5-1 plan
Jonathan Zalevsky
Chief R&D Officer · sold 485 at $30.10
15K
2.5% of stake
Sep 2, 202510b5-1 plan
Howard W Robin
President & CEO · sold 1,500 at $30.16
45K
2.2% of stake
Aug 19, 2025No plan
Jonathan Zalevsky
Chief R&D Officer · sold 725 at $26.59
19K
3.6% of stake
Aug 19, 2025No plan
Mark Andrew Wilson
Chief Legal Officer · sold 676 at $26.59
18K
3.2% of stake
Aug 19, 2025No plan
Howard W Robin
President & CEO · sold 1,573 at $26.59
42K
2.2% of stake
May 19, 2025No plan
Jonathan Zalevsky
Chief R&D Officer · sold 10,712 at $0.67
7K
3.4% of stake
May 19, 2025No plan
Mark Andrew Wilson
Chief Legal Officer · sold 9,996 at $0.67
7K
3.1% of stake
May 19, 2025No plan
Howard W Robin
President & CEO · sold 23,208 at $0.67
16K
2.1% of stake
Feb 19, 2025No plan
Jonathan Zalevsky
Chief R&D Officer · sold 10,300 at $1.01
10K
3.2% of stake
Feb 19, 2025No plan
Mark Andrew Wilson
Chief Legal Officer · sold 11,040 at $1.01
11K
3.3% of stake
Feb 19, 2025No plan
Howard W Robin
President & CEO · sold 23,774 at $1.01
24K
2.1% of stake
Dec 23, 2024 – Dec 24, 2024No plan
Mark Andrew Wilson
Chief Legal Officer · sold 49,962 at avg $0.90
45K
13% of stake
Dec 19, 2024No plan
Jonathan Zalevsky
Chief R&D Officer · sold 51,115 at $0.94
48K
14% of stake
Dec 17, 2024 – Dec 18, 2024No plan
Howard W Robin
President & CEO · sold 132,030 at avg $1.00
132K
11% of stake
Nov 19, 2024No plan
Jonathan Zalevsky
Chief R&D Officer · sold 7,785 at $1.01
8K
3.1% of stake
Nov 19, 2024No plan
Mark Andrew Wilson
Chief Legal Officer · sold 6,407 at $1.01
6K
2.8% of stake
Nov 19, 2024No plan
Howard W Robin
President & CEO · sold 16,278 at $1.01
16K
1.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NKTR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NKTR

CompareIntrinsic value

AQSTAquestive Therapeutics Inc.

$3.80-2.06%10

TNGXTango Therapeutics Inc.

$23.18+0.04%40

QTTBQ32 Bio Inc.

$8.97+2.40%60

GOSSGossamer Bio Inc.

$9.40+1.29%10

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

AYTUAytu BioPharma Inc.

$1.92-0.52%48

OCULOcular Therapeutix Inc.

$7.14+4.69%10

PRTAProthena Corporation plc

$8.39+2.19%25

Held by ETFs

NKTR is in 29 US ETFs. The largest of them, with NKTR's weight in each:

Spot a number that looks wrong? Check it in NKTR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NKTR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.